Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17543702 | 0.91 | KMT2A (0.38) | KMT2AALDH1A1CHRM2CHRM4ADRB1 | |
| SCHEMBL17543121 | 0.88 | KMT2A (0.36) | KMT2AALDH1A1PDE3BPDE3AHSD11B1 | |
| SCHEMBL17542804 | 0.88 | KMT2A (0.36) | KMT2AALDH1A1 | |
| SCHEMBL17543544 | 0.84 | ALDH1A1 (0.42) | KMT2AALDH1A1PDE3BPDE3AHTR2C | |
| SCHEMBL12684538 | 0.81 | ALDH1A1 (0.41) | KMT2AALDH1A1PDE3BPDE3AMAOA | |
| SCHEMBL5622837 | 0.81 | ALDH1A1 (0.41) | KMT2AALDH1A1PDE3BPDE3AMAOA | |
| SCHEMBL17543687 | 0.77 | ALDH1A1 (0.59) | KMT2AALDH1A1 | |
| SCHEMBL29931936 | 0.77 | ALDH1A1 (0.59) | KMT2AALDH1A1 | |
| SCHEMBL17543777 | 0.77 | CPS1 (0.40) | KMT2AALDH1A1PDE3BPDE3AADRB1 | |
| SCHEMBL17543274 | 0.77 | HRH4 (0.31) | HTR2CHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116589448-A | 3, 4-dihydroquinolinone derivative and application thereof | 西南交通大学 | 2023-08-15 | — | — | CN | disclosed |
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-3421454-B1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-04-05 | — | — | EP | disclosed |
| CN-108884044-B | Piperidine derivatives | 大塚制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| US-10851079-B2 | Piperidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10851079-B2 | Piperidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| CN-106795117-B | Heterobicyclic compounds and their use for the treatment of tuberculosis | 大塚制药株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3186240-B1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-07 | — | — | US | disclosed |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-07 | — | — | US | disclosed |
| EP-3421454-A1 | PIPERIDINE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2019-01-02 | — | — | EP | disclosed |
| EP-3421454-A1 | PIPERIDINE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2019-01-02 | — | — | EP | disclosed |
| CN-108884044-A | PIPERIDINE DERIVATIVE | 大塚制药株式会社 | 2018-11-23 | — | — | CN | disclosed |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3186240-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| CN-106795117-A | Heterobicyclic compounds and their use for the treatment of tuberculosis | 大塚制药株式会社 | 2017-05-31 | — | — | CN | disclosed |
| WO-2016031255-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | KMT2A 2525/4885ALDH1A1 1458/4885PDE3B 3735/4885 |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | KMT2A 2525/4885ALDH1A1 1458/4885PDE3B 3735/4885 |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | KMT2A 2525/4885ALDH1A1 1458/4885PDE3B 3735/4885 |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | KMT2A 2525/4885ALDH1A1 1458/4885PDE3B 3735/4885 |
| US-10851079-B2 | Piperidine derivative | EP300, SLC11A2, TBC1D5 | KMT2A 1201/4885ALDH1A1 97/4885PDE3B 703/4885 |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | EP300, SLC11A2, TBC1D5 | KMT2A 1201/4885ALDH1A1 97/4885PDE3B 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.